Phase 1 study of GLPG2534 in patients with atopic dermatitis
Latest Information Update: 05 Jun 2026
At a glance
- Drugs GLPG 2534 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
Most Recent Events
- 07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
- 20 Jun 2016 New trial record
- 15 Jun 2016 According to Galapagos media release, this study is expected to start in 2017.